BlueWind Medical has raised $47.8m to expand commercialisation of its implantable tibial neuromodulation (iTNM) system for urge urinary incontinence (UUI) treatment.
Originating through a combination of equity and debt financing, the Utah-headquartered company will use the proceeds to grow its sales teams and continue investing in market access initiatives that broaden patient and provider access to its Revi system.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BlueWind’s Revi gets implanted near the ankle during a single outpatient procedure. Delivering targeted stimulation to the posterior tibial nerve to alleviate UUI symptoms, the system also features a wearable control that allows patients to personalise their therapy.
The next generation version of Revi obtained US Food and Drug Administration (FDA) clearance in December 2025. It was updated with a simplified user-interface compared to the original system, which secured de novo classification from the FDA in August 2023.
Overactive bladder (OAB), or the frequent urge for an individual to empty their bladder, affects an estimated 33 million people in the US, with around half of those struggling with UUI, wherein bladder leakage occurs, according to the National Association for Continence (NAFC).
Bluewind’s CFO, Stephen Armstrong, commented: “This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in Implantable Tibial Neuromodulation for urgency urinary incontinence.
“The capital allows us to scale our commercial organisation, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy.”
Varying neuromodulation therapies for addressing bladder dysfunction such as UUI, OAB, and stress urinary incontinence (SUI) are gaining traction in the field of urology.
According to a report by GlobalData, the global neurological devices market will reach a valuation of $20.9bn by 2033, up from $12.5bn in 2023.
UroMems is making plans for regulatory filings in the US and Europe for its automated artificial urinary sphincter (AUS) for SUI treatment following the completion of a $60m fundraise on 14 May. Meanwhile, Boston Scientific is continuing to grow its urology portfolio, having acquired Valencia Technologies in January 2026, giving the medtech giant an implantable tibial nerve stimulation (ITNS) system for UUI treatment.
